Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totalling 3,100 shares, a drop of 51.6% from the March 31st total of 6,400 shares. Based on an average daily trading volume, of 12,500 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the company's stock are sold short.
Adlai Nortye Trading Down 4.3 %
NASDAQ ANL traded down $0.09 during trading on Friday, hitting $1.92. The stock had a trading volume of 8,592 shares, compared to its average volume of 13,325. Adlai Nortye has a 12 month low of $1.69 and a 12 month high of $13.92. The company's 50-day moving average price is $2.10 and its two-hundred day moving average price is $2.20.
About Adlai Nortye
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
See Also
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
